A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs Human acellular vessel-Humacyte (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Humacyte
- 12 Nov 2024 Status changed from active, no longer recruiting to completed.
- 17 Aug 2022 Planned End Date changed from 1 Apr 2026 to 1 Dec 2024.
- 28 Feb 2022 According to a Humacyte media release, Prof. Tomasz Jakimowicz, M.D., Ph.D., of the Medical University of Warsaw, Poland, is a principal investigator of the trial.